PHOENIX (PRWEB) December 06, 2017 -- A new cancer center model is helping meet the demand for better quality cancer care in community settings.
An original paper in ADC Review | Journal of Antibody-drug Conjugates, a peer-reviewed journal published by InPress Media Group, LLC, describes the concept.
Hybrid academic-community cancer centers began emerging and evolving at several sites in some southern and mid-Atlantic states during the last several years. In February 2017 a number of their directors, and other key members of their respective institutions, gathered for a CME-sponsored full-day workshop in Miami, Fla., to share experiences and best practices to advance the model.
Cancer centers qualified to be classified as hybrid academic-community cancer centers shared the following attributes:
- Most recruited respected academic-clinician leaders from NCI-designated comprehensive cancer centers;
- They were established at large, well-respected, financially secure not-for-profit regional community hospital systems interested in increasing quality of care and standards of practice;
- They sought to infuse greater academic rigor into their programs, develop translational research programs, enroll more patients from their respective communities into clinical trials, and provide the best cancer care to populations not served by traditional academic centers;
- They often adapted existing resources through collaborative efforts rather than reinventing the wheel.
According to Erich Mounce, Chief Executive Officer of West Cancer Center, “The development of the hybrid cancer center is an important evolution for cancer care. Combining the best practices and services from each model (community and academic) allows the patients to experience the intimacy and connections that so dominate community practice and the scientific specialization, innovative therapies and procedures developed and utilized in so many academic cancer centers. At West Cancer Center, like other evolving hybrid cancer centers, we are following a journey to integrate the best of both types of centers.”
“Since hybrid academic-community cancer centers share common attributes but differ in structure, as the article shows, it’s important that leaders of these centers, as well as those aspiring to hybrid status, continue to meet and discuss the ever-evolving state of this new cancer center model,” said Eric T. Rosenthal, lead author of the study, who added it’s also important to monitor and measure effectiveness in improving patient care in each center’s respective community.
The centers represented were Baptist Health South Florida’s Miami Cancer Institute, Miami, Fla.; West Cancer Center, Memphis, Tenn.; Inova Schar Cancer Institute, Falls Church, Va.; and Gibbs Cancer Center and Research Institute, Spartanburg Regional Healthcare System, Spartanburg, SC.
Participants discussed how and why their centers were created, academic partnerships, future goals, and opportunities and challenges in research, treatment, recruitment, marketing, and fundraising, among other issues.
The conference was organized and moderated by Rosenthal, Editor-at-Large of Onco’Zine (http://www.oncozine.com), who first identified, named, and described the concept in a series of articles appearing in MedPage Today in 2015.
The article “The Nature and Nurturing of Hybrid Academic-Community Cancer Centers,” was co-authored by Rosenthal and the cancer center directors, Michael Zinner, MD, Lee S. Schwartzberg, MD, Donald L. “Skip” Trump, MD, and Timothy J. Yeatman, MD and was published in ADC Review | Journal of Antibody-drug Conjugates | DOI: 10.14229/jadc.2017.11.27.001
About West Cancer Center
West Cancer Center in Memphis, Tenn., is the region’s comprehensive leader in adult cancer care and research, delivering a continuum of care to more than 35,000 individuals each year. Based on the innovative partnership between Methodist Healthcare and the University of Tennessee Health Science Center (UTHSC), West Cancer Center has built a reputation for both clinical excellence and cutting-edge research, providing patients with effective, individualized cancer care. For more information: https://www.westcancercenter.org/
Follow us on twitter @west_cancer and Facebook: https://www.facebook.com/westcancercenter/
About ADC Review | Journal of Antibody-drug Conjugates
ADC Review | Journal of Antibody-drug Conjugate (ISSN 2327-0152) is an international, open-access, peer-reviewed journal published by InPress Media Group, LLC, covering scientific, regulatory, and clinical information about targeted therapies as well as personalized and individualized medicine. Launched in 2013, the journal’s mission is to provide an interdisciplinary forum for the exchange of information among a diverse community of readers, including those in academia, life sciences, pharma, (basic, translational and clinical) research, treatment, and prevention, along with regulatory affairs, government authorities and representatives from payers, and policymakers. For more information, visit the journal’s website: http://www.adcreview.com
Follow us on Twitter @ADCreview and Facebook https://www.facebook.com/ADCReview/
About InPress Media Group, LLC
InPress Media Group is a global medical media and science-publishing company based in Phoenix, Ariz., with deep roots in oncology, hematology, infectious diseases, endocrinology, targeted therapies and personalized medicine. The company specializes in the development of high-science education programs, including creative, editorial and education strategies, and publication planning for medical, pharmaceutical, and life science companies. For more information: http://www.inpressmediagroup.com
Follow us on Twitter @InpressG and Facebook https://www.facebook.com/inpressmediagroup/
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact:
Julie K. Flanery
West Cancer Center
jflanery(at)WESTCLINIC.com
Peter Hofland, Ph.D
InPress Media Group, LLC
peter(at)inpressmediagroup.com
Full Citation:
Rosenthal ET, Schwartzberg LS, Trump DL, Yeatman TJ, Zinner M.
The Nature and Nurturing of Hybrid Academic-Community Cancer Centers (2017)
ADC Review | Journal of Antibody-drug Conjugates | DOI: 10.14229/jadc.2017.11.27.001.
URL of the Publication
http://adc.expert/2Aw3AMy
Julie K. Flanery, West Cencer Center, https://www.westcancercenter.org/, +1 +1 901 683 0055, [email protected]
Share this article